Literature DB >> 29800951

No Evident Disease Activity-More Than a Risky Ambition?

Benjamin Meir Jacobs1, Gavin Giovannoni1,2, Klaus Schmierer1,2.   

Abstract

Mesh：

Year:  2018        PMID： 29800951     DOI： 10.1001/jamaneurol.2018.0829

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  2 in total

Review 1.  Towards a standard MRI protocol for multiple sclerosis across the UK.

Authors:  Klaus Schmierer; Thomas Campion; Audrey Sinclair; Wim van Hecke; Paul M Matthews; Mike P Wattjes
Journal:  Br J Radiol       Date:  2019-05-14       Impact factor: 3.039

2.  Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years.

Authors:  Tommaso Guerra; Francesca Caputo; Bianca Orlando; Damiano Paolicelli; Maria Trojano; Pietro Iaffaldano
Journal:  Neurol Sci       Date:  2021-03-06       Impact factor: 3.307
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.